skip to content
Dovepress - Open Access to Scientific and Medical Research
View our mobile site

8852

Inhaled treprostinil and pulmonary arterial hypertension

Review

(1695) Views  (512) Full article downloads

Authors: Samuel T Nadler, Jeffrey D Edelman

Published Date December 2010 Volume 2010:6 Pages 1115 - 1124
DOI: http://dx.doi.org/10.2147/VHRM.S14777

Samuel T Nadler, Jeffrey D Edelman
University of Washington Division of Pulmonary and Critical Care Medicine, Seattle, WA, USA

Abstract: Multiple conditions result in development of pulmonary hypertension. Pulmonary arterial hypertension (PAH) is the subclassification of pulmonary hypertension, in which known or unknown underlying conditions lead to similar intrinsic alterations in the pulmonary vasculature. PAH is a progressive condition characterized by restricted blood flow through the pulmonary circulation leading to poor survival in the absence of effective therapy. Over the last two decades, new therapeutic agents have substantially improved the course and prognosis for PAH patients. Three available classes of drugs, ie, prostacyclins, endothelin receptor antagonists, and phosphodiesterase-5 inhibitors provide multiple options for treatment of PAH. Endothelin receptor antagonists and phosphodiesterase-5 inhibitors are administered orally, whereas prostacyclin therapies are delivered by continuous intravenous or subcutaneous infusion, or as aerosols by nebulization. Because of the risks and inconveniences associated with administration, prostacyclins are typically reserved for patients with more advanced disease or progression despite oral therapy. Inhaled administration may be a safer and easier route for prostacyclin administration. Treprostinil is a prostacyclin analog that has been demonstrated to be effective when administered by continuous subcutaneous or intravenous infusion, and more recently by nebulization.

Keywords: pulmonary arterial hypertension, bosentan, prostacyclin, treprostinil, 6MWD






Readers of this article also read:

Role of aliskiren in cardio-renal protection and use in hypertensives with multiple risk factors
Berberine: metabolic and cardiovascular effects in preclinical and clinical trials
The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension
Health literacy and health seeking behavior among older men in a middle-income nation
Cardiac risk stratification: Role of the coronary calcium score
Effectiveness and tolerability of a fixed-dose combination of olmesartan and amlodipine in clinical practice
Insulin therapy in critically ill patients
Optimal management of familial hypercholesterolemia: treatment and management strategies
New treatment options in the management of hypertension: appraising the potential role of azilsartan medoxomil
Cardiac ryanodine receptor in metabolic syndrome: is JTV519 (K201) future therapy?
  • Join ISVH

    Be part of the World's leading experts in vascular health by joining the International Society of Vascular Health (ISVH)

  • Testimonials

    "... I was impressed at the rapidity of publication from submission to final acceptance." Dr Edwin Thrower, PhD, Yale University